According to GlobalData’s medical device pipeline database, 93 Metabolic Disorder devices are in various stages of development globally. GlobalData’s report Metabolic Disorder provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 33 are in active development, while the remaining 61 are in an inactive stage of development. There are 22 products in the early stages of development, and the remaining 11 are in the late stages of development.
In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. A metabolic disorder test is a type of blood test that checks for the presence of certain substances in the blood that can indicate a metabolic disorder. Metabolic Disorder tests are carried out to diagnose and monitor metabolic disease, that impact how the body processes and distribute macronutrients, such as proteins, fats, and carbohydrates. Metabolic Disorder tests includes Diabetes Assays segment and Cholesterol tests segment.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Metabolic Disorder pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Metabolic Disorder devices. Overall, most of these Metabolic Disorder pipeline devices are being developed by private entities.
Key players involved in the active development of Metabolic Disorder include Beckman Coulter, Guangzhou Wondfo Biotech, Aura Biotechnologies, Genesis Detection Systems, QuickCheck Health, CellCarta Precision Medicine, Enable Biosciences, Human Cell Design, Indian Institute of Technology Bombay and Intelligent Bio Solutions.
For a complete picture of the developmental pipeline for Metabolic Disorder devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
